In an observational study comparing individuals with type 2 diabetes and obesity who underwent metabolic surgery with similar individuals who received GLP-1 receptor agonist treatment, metabolic surgery was associated with a lower risk of macrovascular and microvascular outcomes, including major adverse cardiovascular events, nephropathy, retinopathy and all-cause mortality.